	US 11,891,441 B2
	Human interleukin-4 receptor alpha antibodies
Shane Krummen Atwell, Carlsbad, CA (US); Yiqing Feng, Carmel, IN (US); Maya Rachel Karta, San Diego, CA (US); Donmienne Leung, San Diego, CA (US); Songqing Na, San Diego, CA (US); Diana Isabel Ruiz, San Diego, CA (US); David John Stokell, Indianapolis, IN (US); and Laura Anne Pelletier, San Diego, CA (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Aug. 5, 2022, as Appl. No. 17/817,754.
Claims priority of provisional application 63/348,388, filed on Jun. 2, 2022.
Claims priority of provisional application 63/229,836, filed on Aug. 5, 2021.
Prior Publication US 2023/0064378 A1, Mar. 2, 2023
Int. Cl. C07K 16/24 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/06 (2006.01); C12N 15/85 (2006.01)

CPC C07K 16/247 (2013.01) [A61K 47/6803 (2017.08); A61P 35/00 (2018.01); C07K 16/06 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C12N 2015/8518 (2013.01)]

69 Claims

1. An antibody or antigen binding fragment thereof that specifically binds human IL-4Rα, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:

the HCDR1 comprises SEQ ID NO: 1;

the HCDR2 comprises SEQ ID NO: 2;

the HCDR3 comprises SEQ ID NO: 3;

the LCDR1 comprises SEQ ID NO: 4;

the LCDR2 comprises SEQ ID NO: 5; and

the LCDR3 comprises SEQ ID NO: 6.